Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
523 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 523 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children… | Phase 2 | terminated | Aug 31, 2015 | Children's Mercy Hospital Kansas City | Funding source discontinued | Funding |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory… | Phase 1 | withdrawn | Dec 14, 2017 | City of Hope Medical Center | contract not executed | Other (stated, no rule matched) |
| NCT02993536 | Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab | — | withdrawn | Dec 15, 2016 | Abramson Cancer Center at Penn Medicine | Low likelihood to usedrug in clinic practice based on emergining AE profile and data from front… | Other (stated, no rule matched) |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage… | Phase 1 | suspended | Nov 1, 2013 | National University Health System, Singapore | Suspended for an interim review of (CAR) CD19 research strategy for the treatment of CD19 positive… | Sponsor / business decision |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | withdrawn | Jan 27, 2009 | Scripps Health | Unable to enroll | Enrollment / accrual |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or… | Phase 2 | terminated | Aug 10, 2015 | St. Jude Children's Research Hospital | Due to slow accrual | Enrollment / accrual |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and… | Phase 4 | terminated | Jan 26, 2011 | Hoffmann-La Roche | not stated | Not stated |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal… | Phase 2 | withdrawn | Jun 15, 2017 | Matinas BioPharma Nanotechnologies, Inc. | Protocol redundancy | Other (stated, no rule matched) |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | Phase 1 / Phase 2 | terminated | Apr 1, 2008 | Alexion Pharmaceuticals, Inc. | The study was terminated by the Sponsor for administrative reasons and not due to any safety… | Safety / toxicity |
| NCT00928200 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND… | Phase 1 | terminated | Jun 25, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Study was terminated due to lack of accrual. | Enrollment / accrual |
| NCT02989675 | SugarFACT - Sugar Requirements For African Children Trial | N/A | terminated | Dec 12, 2016 | Helena Hildenwall | not stated | Not stated |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With… | Phase 1 / Phase 2 | terminated | Jul 27, 2011 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Slow patient enrollment and new molecules for chronic lymphoid leukemia, have importantly reduced… | Enrollment / accrual |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic… | Phase 1 | withdrawn | Nov 23, 2015 | Michael Choi | No participants enrolled | Enrollment / accrual |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory… | Phase 1 | terminated | May 27, 2015 | Janssen Research & Development, LLC | Recent advances in the treatment of B cell malignancies resulting in new treatments being approved… | Other (stated, no rule matched) |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Phase 2 | terminated | Sep 17, 2010 | Gilead Sciences | not stated | Not stated |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With… | Phase 2 | terminated | Jul 24, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Funding was unavailable to complete the study as originally planned. | Funding |
| NCT02632903 | Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in… | Phase 2 | withdrawn | Dec 17, 2015 | Children's Hospital of Eastern Ontario | While the clinical need for and the scientific merit remain valid, this regulated drug trial was… | Funding |
| NCT00900445 | Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk… | — | withdrawn | May 12, 2009 | Children's Oncology Group | not stated | Not stated |
| NCT01037764 | Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic…(AHCTALL) | Phase 2 | terminated | Dec 23, 2009 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01761682 | Acute Lymphoblastic Leukemia Registry at Asan Medical Center | — | terminated | Jan 7, 2013 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT02428517 | Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia…(ATLAS2015) | — | terminated | Apr 28, 2015 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood… | Phase 2 | terminated | Dec 10, 2012 | Weill Medical College of Cornell University | Slow accrual | Enrollment / accrual |
| NCT01910428 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult… | Phase 1 | terminated | Jul 29, 2013 | ERYtech Pharma | Sponsor decision based off site/PI feedback about | Sponsor / business decision |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | Phase 1 / Phase 2 | terminated | Jan 15, 2010 | Everett Meyer | Safety | Safety / toxicity |
| NCT01326728 | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | — | terminated | Mar 31, 2011 | National Cancer Institute (NCI) | A replacement protocol was created to replace this current version of protocol. | Other (stated, no rule matched) |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia | Phase 2 | withdrawn | Jul 14, 2010 | Stanford University | no accrual | Enrollment / accrual |
| NCT01195480 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)(CD19TPALL) | Phase 1 / Phase 2 | terminated | Sep 6, 2010 | University College, London | Due to lack of biological efficacy and CD19 CAR CTL persistence | Efficacy / futility |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic… | Phase 2 | terminated | Sep 25, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual, PI left NIH and primary endpoint not met. | Investigator |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT01612988 | Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL(BOMP) | Phase 2 | terminated | Jun 6, 2012 | French Innovative Leukemia Organisation | Other drugs others studies | Other (stated, no rule matched) |
| NCT02462265 | Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid… | Phase 2 | suspended | Jun 4, 2015 | Oshadi Drug Administration | not stated | Not stated |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | Phase 2 | terminated | Jan 15, 2008 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
| NCT02020109 | Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia | — | withdrawn | Dec 24, 2013 | Maastricht Radiation Oncology | Logistics and financial | Funding |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants… | Phase 4 | terminated | Jan 6, 2011 | Hoffmann-La Roche | not stated | Not stated |
| NCT01069432 | Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic… | — | withdrawn | Feb 17, 2010 | Dartmouth-Hitchcock Medical Center | IRB delayed their review for an extensive period of time. Funding for this protocol is no longer… | Funding |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine:… | Phase 2 | withdrawn | Oct 21, 2014 | Jazz Pharmaceuticals | not stated | Not stated |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged… | Phase 2 | terminated | Apr 17, 2015 | St. Jude Children's Research Hospital | Accrual goals were no longer feasible based on restrictions imposed by the DSMB. | Enrollment / accrual |
| NCT02137889 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or…(VAY736Y) | Phase 1 | terminated | May 14, 2014 | Novartis Pharmaceuticals | Study terminated on 04Oct2013 for business reasons after being on hold for 10 months. Early… | Safety / toxicity |
| NCT02371590 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | Phase 2 | withdrawn | Feb 25, 2015 | University of California, San Diego | Study Not Activated Due to Contract Issues | Other (stated, no rule matched) |
| NCT01685021 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic… | Phase 2 | terminated | Sep 13, 2012 | MorphoSys AG | not stated | Not stated |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated…(POE07-01) | Phase 1 | terminated | Feb 27, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Lack of accrual | Enrollment / accrual |
| NCT02578511 | Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With… | Phase 1 | withdrawn | Oct 19, 2015 | Ehab L Atallah | No enrollment, another competing study and difficult to find the right person to enroll on this… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 13, 2019source: clinicaltrials